Xbrane secures GMP import authorization
Xbrane Biopharma has received authorization from the Swedish Medical Products Agency to import medicinal products from outside the EU/EEA and to certify and release batches for supply within the EU. The approval is expected to simplify the supply chain for its ranibizumab biosimilar Ximluci/Lucamzi, including deliveries of finished product to the US.
With the authorization, the Solna-based biosimilar developer can take a more active role in the pharmaceutical supply chain. It can now import products manufactured in third countries into the EU, and a Qualified Person (QP) can certify and release them in line with EU Good Manufacturing Practice (GMP) requirements.
For Ximluci, the change gives Xbrane the chance to streamline its existing commercial supply chain and gain more control over import and release activities.
The new setup can also support Xdarzane, Xbrane’s daratumumab biosimilar candidate, and future biosimilars. Partners can now get EU import, QP certification, and batch release from Xbrane, on top of biosimilar development and the setup of commercial manufacturing processes.
Published: November 18, 2026
